Posted by Michael Wonder on 22 Feb 2023
Ixazomib citrate and lenalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
22 February 2023 - This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access agreement for the combination of ixazomib citrate and lenalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (TA505).
Ixazomib citrate, when used in combination with lenalidomide and dexamethasone, is recommended as an option for the treatment of adults with multiple myeloma only if they have had two or three lines of therapy and Takeda provides ixazomib citrate according to the commercial arrangement.
